1. Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.
- Author
-
Navarro Sanchez JM, Finkelman BS, Tyburski H, Turner BM, Moisini I, Katerji H, Varghese S, Wang X, Schiffhauer LM, Chen JJ, Hicks DG, and Zhang H
- Subjects
- Humans, Female, Sensitivity and Specificity, Gene Amplification, Immunohistochemistry, In Situ Hybridization, Fluorescence, Uterine Neoplasms genetics, Uterine Neoplasms pathology, Uterine Neoplasms diagnosis, Receptor, ErbB-2 genetics, Receptor, ErbB-2 analysis, Biomarkers, Tumor analysis, Biomarkers, Tumor genetics, Cystadenocarcinoma, Serous genetics, Cystadenocarcinoma, Serous diagnosis, Cystadenocarcinoma, Serous pathology
- Abstract
We compared the performance of two commonly-used HER2 immunohistochemistry (IHC) assays in uterine serous carcinomas (USC), correlating with HER2 gene amplification by fluorescence in-situ hybridization (FISH). Sixty-five USCs were stained by both HercepTest™ and PATHWAY 4B5 assays. FISH was performed by HER2 IQFISH pharmDx. Consensus HER2 IHC scoring was performed, and HER2 testing results were evaluated using USC-specific criteria. Complete concordance between HercepTest and 4B5 assays was achieved in 44/65 tumors (68%). The overall HER2 IHC/FISH concordance was 94% (45/48) by HercepTest and 91% (42/46) by 4B5. All HER2 IHC 3+ cases with HercepTest (n = 6) and 4B5 (n = 4) were gene-amplified, corresponding to specificities of 100%. For cases with IHC 2+, 41% (7/17) by HercepTest and 42% (8/19) by 4B5 had HER2 gene amplification. The sensitivity for HercepTest and 4B5 were 38% and 25%, respectively, at a cut-off of IHC 3+ (P = 0.50), and were 81% and 75%, respectively, at a cut-off of IHC 2+ (P > 0.99). Among HER2 IHC 0-1+ cases, 3/42 cases by HercepTest and 4/42 cases by 4B5 showed amplified FISH results, corresponding to overall false negative rates of 19% for HercepTest and 25% for 4B5. By using USC-specific IHC scoring criteria, both HercepTest and 4B5 assays showed high specificities (100%) for HER2 gene amplification in IHC 3+ cases, high IHC/FISH concordance, and comparable sensitivity for detecting HER2 gene amplification. The notable false negative rates using IHC 2+ as a cut-off for reflexing FISH analysis may warrant consideration for performing FISH in IHC 1+ cases until more data become available., Competing Interests: Declaration of competing interest HZ serves on the Within3 Pathologist Virtual Advisory Board of AstraZeneca. DGH serves on the Advisory Board and Speaks Bureau of AstraZeneca. There is no conflict of interest associated with this publication. All other authors declare no competing interests., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF